Porton Pharma Solutions Ltd(300363) announced that in order to match the rapid growth of pre clinical and early clinical (CRO) business development needs, the company plans to purchase 100% equity of Kaihui Pharmaceutical (Shanghai) Co., Ltd. held by Shanghai Ruizhi Chemical Research Co., Ltd. in cash at the price of 266 million yuan. Kaihui pharmaceutical is a wholly-owned secondary subsidiary of Chempartner Pharmatech Co.Ltd(300149) ( Chempartner Pharmatech Co.Ltd(300149) ). As a global R & D and production service provider of small molecule drugs, Kaihui pharmaceutical is mainly committed to providing customers with process R & D and production services of intermediates and APIs required from preclinical research to various clinical trial stages. Kaihui pharmaceutical is currently in the state of shutdown due to the transformation of plant and facilities.
© China Stock Market News